The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis

被引:596
作者
Zaoutis, TE
Argon, J
Chu, J
Berlin, JA
Walsh, TJ
Feudtner, C
机构
[1] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Gen Pediat, Pediat Generalists Res Grp, Philadelphia, PA 19104 USA
[3] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Biostat, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[6] NCI, Pediat Oncol Branch, Immunocompromised Host Sect, Bethesda, MD 20892 USA
关键词
D O I
10.1086/496922
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Candida species are the fourth most common cause of bloodstream infection and are the leading cause of invasive fungal infection among hospitalized patients in the United States. However, the frequency and outcomes attributable to the infection are uncertain. This retrospective study set out to estimate the incidence of candidemia in hospitalized adults and children in the United States and to determine attributable mortality, length of hospital stay, and hospital charges related to candidemia. Methods. We used the Nationwide Inpatient Sample 2000 for adult patients and the Kids' Inpatient Database 2000 for pediatric patients. We matched candidemia-exposed and candidemia-unexposed patients by the propensity scores for the probability of candidemia exposure, which were derived from patient characteristics. Attributable outcomes were calculated as the differences in estimates of outcomes between propensity score-matched patients with and without candidemia. Results. In the United States in 2000, candidemia was diagnosed in an estimated 1118 hospital admissions of pediatric patients and 8949 hospital admissions of adult patients, yielding a frequency of 43 cases per 100,000 pediatric admissions (95% confidence interval [CI], 35-52 cases per 100,000 pediatric admissions) and 30 cases per 100,000 adult admissions (95% CI, 26-34 cases per 100,000 adult admissions). In pediatric patients, candidemia was associated with a 10.0% increase in mortality (95% CI, 6.2%-13.8%), a mean 21.1-day increase in length of stay (95% CI, 14.4-27.8 days), and a mean increase in total per-patient hospital charges of $92,266 (95% CI, $65,058 -$119,474). In adult patients, candidemia was associated with a 14.5% increase in mortality (95% CI, 12.1%-16.9%), a mean 10.1-day increase in length of stay (95% CI, 8.9-11.3 days), and a mean increase in hospital charges of $39,331 (95% CI, $33,604-$45,602). Conclusion. The impact of candidemia on excess mortality, increased length of stay, and the burden of cost of hospitalization underscores the need for improved means of prevention and treatment of candidemia in adults and children.
引用
收藏
页码:1232 / 1239
页数:8
相关论文
共 36 条
[1]  
BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247
[2]   Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery [J].
Booy, R ;
Habibi, P ;
Nadel, S ;
de Munter, C ;
Britto, J ;
Morrison, A ;
Levin, M .
ARCHIVES OF DISEASE IN CHILDHOOD, 2001, 85 (05) :386-390
[3]   Nosocomial bloodstream infections in United States hospitals: A three-year analysis [J].
Edmond, MB ;
Wallace, SE ;
McClish, DK ;
Pfaller, MA ;
Jones, RN ;
Wenzel, RP .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :239-244
[4]  
ELIXHAUSER A, 1993, CLIN CLASSIFICATIONS
[5]   Characteristics of deaths occurring in children's hospitals: Implications for supportive care services [J].
Feudtner, C ;
Christakis, DA ;
Zimmerman, FJ ;
Muldoon, JH ;
Neff, JM ;
Koepsell, TD .
PEDIATRICS, 2002, 109 (05) :887-893
[6]   A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
GOODMAN, JL ;
WINSTON, DJ ;
GREENFIELD, RA ;
CHANDRASEKAR, PH ;
FOX, B ;
KAIZER, H ;
SHADDUCK, RK ;
SHEA, TC ;
STIFF, P ;
FRIEDMAN, DJ ;
POWDERLY, WG ;
SILBER, JL ;
HOROWITZ, H ;
LICHTIN, A ;
WOLFF, SN ;
MANGAN, KF ;
SILVER, SM ;
WEISDORF, D ;
HO, WG ;
GILBERT, G ;
BUELL, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851
[7]   Attributable mortality of nosocomial candidemia, revisited [J].
Gudlaugsson, O ;
Gillespie, S ;
Lee, K ;
Berg, JV ;
Hu, JF ;
Messer, S ;
Herwaldt, L ;
Pfaller, M ;
Diekema, D .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :1172-1177
[8]   Improved outcomes of children with malignancy admitted to a pediatric intensive care unit [J].
Hallahan, AR ;
Shaw, PJ ;
Rowell, G ;
O'Connell, A ;
Schell, D ;
Gillis, J .
CRITICAL CARE MEDICINE, 2000, 28 (11) :3718-3721
[9]   Fluconazole prophylaxis against fungal colonization and infection in preterm infants [J].
Kaufman, D ;
Boyle, R ;
Hazen, KC ;
Patrie, JT ;
Robinson, M ;
Donowitz, LG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1660-1666
[10]   Risk factors for candidemia in a children's hospital [J].
MacDonald, L ;
Baker, C ;
Chenoweth, C .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (03) :642-645